Abstract
Single-photon emission tomography (SPET) with technetium-99m sestamibi (MIBI) was carried out in 61 adult patients with supratentorial expanding brain lesions. Thirty-one patients had pathologically proven malignant glioma. Ten patients had pathologically proven low-grade glioma, while another 12 patients had a clinical diagnosis of low-grade glioma. The other eight patients had a variety of lesions including radiation necrosis (3), abscess (2), ischaemic stroke (2) and primary brain lymphoma (1). SPET was performed 15 min after administration of 740–930 MBq MIBI and transverse, sagittal and coronal views were reconstructed. Using computed tomography or magnetic resonance imaging guidance, a MIBI uptake index was computed as the ratio of counts in the lesion to counts in the contralateral homologous region. In high-grade gliomas, the MIBI index ranged from 1.9 to 6.6 (mean 3.6 ± 1.4) whereas it ranged from 0.8 to 1.7 (1.1 ± 0.2) in the pathologically proven low-grade group (P < 0.01). No significant difference was found between the two low-grade groups (1.1 ± 0.2 vs 1.1 ± 0.2). No overlap was found between high-grade and low-grade glioma index values. Patients with suspected radiation necrosis, cerebral abscess or ischaemic stroke did not demonstrate high MIBI uptake (0.9–2.2), whereas one patient with brain lymphoma did (3.9). This study suggests that MIBI SPET imaging is of value in distinguishing low-from high-grade supratentorial gliomas in adults.
Similar content being viewed by others
References
Friedman WA, Sceat DJ Jr, Nestok BR, Ballinger WE Jr. The incidence of unexpected pathological findings in an image guided biopsy series: a review of 100 cases. Neurosurgery 1989; 25: 180–184.
Black CL, Hawkins RA, Kim KT, Becker DP, Lerner C, Marciano D. Use of thallium-201 SPELT to quantitate malignancy grade of gliomas. J Neurosurg 1989; 7: 342–346.
Chamberlain MC, Murovic JA, Levin VA. Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology 1988; 38: 1371–1374.
Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, Patronas NJ, Kufta CV, Kessler RM, Johnston GS, Manning RG, Wolf AP. Glucose utilization of cerebral gliomas measured by (18F)fluorodeoxyglucose and positron emission tomography. Neurology 1982; 32: 1323–1329.
Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, Larson SM. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985; 62: 816–822.
Doyle WK, Budinger TF, Valk PE, Levin VA, Gutin PH. Differentiation of cerebral radiation necrosis from tumor recurrence by (18F)FDG and 82Rb positron emission tomography. J Comput Assist Tomogr 1987; 11: 563–570.
Francavilla TL, Miletich RS, Di Chiro G, Patronas NJ, Rizzoli HV, Wright DC. Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery 1989; 24: 1–5.
Valk PE, Budinger TF, Levin VA, Silver P, Gutin PH, Doyle WK. PET of malignant cerebral tumors after interstitial brachytherapy. J Neurosurg 1988; 69: 830–838.
Rozental JM, Levine RL, Nickles RJ, Dobkin JA. Glucose uptake by gliomas after treatment. A positron emission tomographic study. Arch Neurol 1989; 46: 1302–1307.
Glantz MJ, Hoffman JM, Coleman RE, Friedman AH, Hanson MW Burger PC, Herndon JE II, Meisler WJ, Schold SC. Identification of early recurrence of primary central nervous system tumors by (18F)fluorodeoxyglucose positron emission tomography. Ann Neurol 1991; 29: 347–355.
Minn H, Paul R. Cancer treatment monitoring with fluorine-18 2-fluoro-2-deoxy-D-glucose and positron emission tomography: frustration or future? Eur J Nucl Med 1992; 19: 921–924.
Kaplan WD, Takvorian T, Morris JH, Rumbaugh CL, Connoly BT, Atkins HL. Thallium-201 brain tumor imaging: a comparative study with pathologic correlation. J Nucl Med 1987; 28: 47–52.
Mountz JM, Stafford-Schuck K, McKeever PE, Taren J, Beierwaltes WH: Thallium-201 tumor/cardiac ratio estimation of residual astrocytoma. J Neurosurg 1988; 68: 705–709.
Carvalho PA, Schwartz RB, Alexander E III, Garada BM, Zimmerman RE, Loeffler JS, Holman BL. Detection of recurrent gliomas with quantitative thallium-201/technetium-99m HMPAO single-photon emission computerized tomography. J Neurosurg 1992; 77: 565–570.
Yoshii Y Satou M, Yamamoto T, Yamada Y, Hyodo A, Nose T, Ishikawa H, Hatakeyama R. The role of thallium-201 single photon emission tomography in the investigation and characterization of brain tumors in man and their response to treatment. Eur J Nucl Med 1993; 20: 39–45.
Ueda T, Kaji Y, Wakisaka S, Watanabe K, Hoshi H, Jinnouchi S, Futami S. Time sequential single photon emission computed tomography studies in brain tumors using thallium-201. Eur J Nucl Med 1993; 20: 138–145.
Oriuchi N, Tamura M, Shibazaki T, Ohye C, Watanabe N, Tateno M, Tomiyoshi K, Hirano T, Inoue T, Endo K. Clinical evaluation of thallium-201 SPELT in supratentorial gliomas: relationship to histologic grade, prognosis and proliferative activities. J Nucl Med 1993; 34: 2085–2089.
O'Driscoll CM, Baker F, Casey MJ, Duffy GJ. Localization of recurrent medullary thyroid carcinoma with technetium-99mm-ethoxyisobutilenitrile scintigraphy: a case report. J Nucl Med 1991; 32: 2281–2283.
Müller SP, Guth-Tougelides B, Creutzig H. Imaging of malignant tumors with Tc-99m MIBI SPELT [abstract]. J Nucl Med 1987; 28: 562.
Müller SP, Reiners C, Paas M, Guth-Tougelidis B, Budach V, Konietzko N, Alberti W. Tc-99m MIBI and T1–201 uptake in bronchial carcinoma [abstract]. J Nucl Med 1989; 30: 845.
Podoloff DA, Kim EE, Haynie TP, Benjamin RS, Bhadkamkar VA. Comparison of Tc-99m sestamibi SPELT and F-18-FDG glucose PET in the evaluation of patient with malignancy [abstract]. J Nucl Med 1992; 33: 858.
O'Tuama LA, Packard AB, Treves ST. SPELT imaging of pediatric brain tumor with hexakis (methoyisobutylisonitrile) technetium (I). J Nucl Med 1990; 31: 2040–2041.
Macapinlac H, Scott A, Caluser C, Finlay J, DeLaPaz R, Lindsley K, Al-mohannadi, Macalintal S, Kalagian H, Yeh S, Larson S, Abdel-Dayem H. Comparison of TI-201 and Tc-99m-2-methoxyisobutylisonitrile (MIBI) with MRI in the evaluation of recurrent brain tumors [abstract]. J Nucl Med 1992; 33: 867.
O'Tuama LA, Treves ST, Larar JN, Packard AB, Kwan AJ, Barnes PD, Scott RM, Black PM, Madsen JR, Goumnerova LC, Sallan SE, Tarbell NJ. Thallium-201 versus technetium-99m-MIBI SPELT in evaluation of childhood brain tumors: a within-subject comparison. J Nucl Med 1993; 34: 1045–1051.
Maublant J, Zhang Z, Rapp M, Ollier M, Michelot J, Veyre A. In vitro uptake of technetium-99m-teboroxime in carcinoma cell lines and normal cells: comparison with technetium-99m-sestamibi and thallium-201. J Nucl Med 1993; 34: 1949–1952.
Kim KT, Black CL, Marciano D, Mazziotta JC, Guze BH, Grafton S, Hawkins RA, Becker DP. Thallium-201 SPELT imaging of brain tumors: methods and results. J Nucl Med 1990; 31: 965–969.
Chin ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium (I) in cultured mouse fibroblasts. J Nucl Med 1990; 31: 1646–1653.
Piwnica-Worms D, Holman BL. Editorial: noncardiac applications of hexakis-(alkylisonitrile) technetium-99m complexes. J Nucl Med 1990; 31: 1166–1167.
Crane P, Laliberte R, Heminway S, Thoolen M, Orlandi C. Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention. Eur J Nucl Med 1993; 20: 20–25.
Scott AM, Kostakoglu L, O'Brien JP, Straus DJ, Abdel-Dayem HM, Larson SM. Comparison of technetium-99m-MIBI and thallium-201-chloride uptake in primary thyroid lymphoma. J Nucl Med 1992; 33: 1396–1398.
Caner B, Kitapcl M, Unlu M, Erbengi G, Calicoglu T, Gogus T, Bekdik C. Technetium-99m-MIBI uptake in benign and malignant bone lesions: a comparative study with technetium-99m-MDP. J Nucl Med 1992; 33: 319–324.
Chen LB. Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 1988; 4: 155–181.
Ericson K, Lilja A, Bergström M, Collins VP, Eriksson L, Ehrin E, von Holst H, Lundqvist H, Langstrom B, Mosskin M. Positron emission tomography with ((11C) methyl)-L-methio-nine, (11C)D-glucose, and (68Ga)EDTA in supratentorial tumors. J ComputAssist Tomogr 1985; 9: 683–689.
Maziotta JC. Editorial — the continuing challenge of primary brain tumor management: the contribution of positron emission tomography. Ann Neurol 1991; 29: 345–361.
Di Chiro G. Editorial — which PET radiopharmaceutical for brain tumors? J Nucl Med 1991; 32: 1346–1347.
Di Chiro G, Oldfield E, Whright DC, De Michele D, Katz DA, Patronas NJ, Doppman JL, Larson SM, Masaroni I, Kufta CV. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJNR 1987; 8: 1083–1091.
Krishna L, Slizofski WJ, Katsetos CD, Nair S, Dadparvar S, Brown SJ, Chevres A, Roman R. Abnormal intracerebral thallium localization in a bacterial brain abscess. J Nucl Med 1992; 33: 2017–2019.
Rosenfeld SS, Hoffman JM, Coleman RE, Glantz MJ, Hanson MW, Schold SC. Studies of primary central nervous system lymphoma with fluorine-l8-fluorodeoxyglucose positron emission tomography. J Nucl Med 1992; 33: 532–536.
Author information
Authors and Affiliations
Additional information
Permanent address: This paper was presented in part at the EANM Congress in Lausanne
Rights and permissions
About this article
Cite this article
Baillet, G., Albuquerque, L., Chen, Q. et al. Evaluation of single-photon emission tomography imaging of supratentorial brain gliomas with technetium-99m sestamibi. Eur J Nucl Med 21, 1061–1066 (1994). https://doi.org/10.1007/BF00181060
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00181060